Esperion Therapeutics: Past The Turnaround, Waiting On Guidelines [Seeking Alpha]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Seeking Alpha
ESPR has resolved generic threats, expanded labels, improved commercial traction, and strengthened its balance sheet, but royalty and debt burdens persist. Prescription growth is robust, but absolute revenue remains modest; sustainable profitability is guided for early 2026, with margins and FCF still constrained. Given recent share price appreciation and pending guideline risk, I rate ESPR a Hold until guideline clarity unlocks further upside. Richard Drury/DigitalVision via Getty Images Investment Thesis Esperion Therapeutics, Inc. ( ESPR ) is a successful turnaround story, and it has nearly doubled on the basis. We must understand, though, that while the share price has recovered, its commercial turnaround is still an ongoing event. So This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article m
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion to Participate in The 2026 Citizens Life Sciences ConferenceGlobeNewswire
- Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040GlobeNewswire
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- How The New Price Target Is Shaping The Story For Esperion Therapeutics (ESPR) [Yahoo! Finance]Yahoo! Finance
- Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
ESPR
Earnings
- 11/6/25 - Miss
ESPR
Sec Filings
- 1/21/26 - Form 4
- 1/20/26 - Form 144
- 1/12/26 - Form 8-K
- ESPR's page on the SEC website